Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-COVID-19: SARS-CoV-2-specific T Lymphocyte Transfer in COVID-19
NCT04762186Phase 1Terminated
- Sponsor
- University Hospital Cologne
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of human SARS-CoV-2-specific T lymphocytes in coronavirus disease 2019 (COVID-19), sponsored by University Hospital Cologne. Primary endpoint: Dose-limiting toxicities at 28 days. Started Dec 2021; status: terminated.
02
Drugs
human SARS-CoV-2-specific T lymphocytes
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04762186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762186.